The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme
Open accessAbstract
Aims: Sodium-glucose co-transporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in diverse patient populations, but their mechanism of action requires further study. The aim is to explore the effect of empagliflozin on the circulating levels of intracellular proteins in patients with heart failure, using large-scale proteomics. Methods and results: Over 1250 circulating proteins were measured at baseline, Week 12, and Week 52 in 1134 patients from EMPEROR-Reduced and EMPEROR-Preserved, using the Olink® Explore 1536 platform. Statistical and bioinformatical analyses identified differentially expressed proteins (empagliflozin vs. placebo), which were then linked to demonstrated biological actions in the heart and kidneys. At Week 12, 32 of 1283 proteins fulfilled our threshold for being differentially expressed, i.e. their levels were changed by ≥10% with a false discovery rate <1% (empagliflozin vs. placebo). Among these, nine proteins demonstrated the largest treatment effect of empagliflozin: insulin-like growth factor-binding protein 1, transferrin receptor protein 1, carbonic anhydrase 2, erythropoietin, protein-glutamine gamma-glutamyltransferase 2, thymosin beta-10, U-type mitochondrial creatine kinase, insulin-like growth factor-binding protein 4, and adipocyte fatty acid-binding protein 4. The changes of the proteins from baseline to Week 52 were generally concordant with the changes from the baseline to Week 12, except empagliflozin reduced levels of kidney injury molecule-1 by ≥10% at Week 52, but not at Week 12. The most common biological action of differentially expressed proteins appeared to be the promotion of autophagic flux in the heart, kidney or endothelium, a feature of 6 proteins. Other effects of differentially expressed proteins on the heart included the reduction of oxidative stress, inhibition of inflammation and fibrosis, and the enhancement of mitochondrial health and energy, repair, and regenerative capacity. The actions of differentially expressed proteins in the kidney involved promotion of autophagy, integrity and regeneration, suppression of renal inflammation and fibrosis, and modulation of renal tubular sodium reabsorption. Conclusions: Changes in circulating protein levels in patients with heart failure are consistent with the findings of experimental studies that have shown that the effects of SGLT2 inhibitors are likely related to actions on the heart and kidney to promote autophagic flux, nutrient deprivation signalling and transmembrane sodium transport.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845 · cited 1×
“Sodium-glucose co-transporter 2 (SGLT2) inhibitors improve cardiovascular outcomes across a wide range of high-risk patients, including those with Type 2 diabetes, chronic kidney disease, and heart failure with a reduced or preserved ejection fraction.(1) These benefits have been characterized by a decrease in the ris…”
BackgroundLamounier-Zepter, V., Look, C., Alvarez, J., Christ, T., Ravens, U., Schunck, W.-H., Ehrhart-Bornstein, M., Bornstein, S. R., & Morano, I. (2009) · Circulation Research · doi:10.1161/circresaha.109.200501 · Cited by 203
Pessoa, T. D., Campos, L. C. G., Carraro-Lacroix, L., Girardi, A. C. C., & Malnic, G. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013060588 · Cited by 184
Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes
Li, J., Neal, B., Perkovic, V., de Zeeuw, D., Neuen, B. L., Arnott, C., Simpson, R., Oh, R., Mahaffey, K. W., & Heerspink, H. J. L. (2020) · Kidney International · doi:10.1016/j.kint.2020.04.051 · Cited by 130
Packer, M. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa064 · Cited by 86
Self-citationFitchett, D., Inzucchi, S. E., Zinman, B., Wanner, C., Schumacher, M., Schmoor, C., Ohneberg, K., Ofstad, A. P., Salsali, A., George, J. T., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13615 · Cited by 85
Cited by
Packer, M. (2022) · Circulation · doi:10.1161/circulationaha.122.061732 · Cited by 425
Self-citationHallmarks of cardiovascular ageing
Abdellatif, M., Rainer, P. P., Sedej, S., & Kroemer, G. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00881-3 · Cited by 274
Metadata
- Authors
- Zannad, F., Ferreira, J. P., Butler, J., Filippatos, G., Januzzi, J. L., Sumin, M., Zwick, M., Saadati, M., Pocock, S. J., Sattar, N., Anker, S. D., & Packer, M.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-08-26
- Volume
- 43
- Issue
- 48
- Pages
- 4991-5002
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W4293194528
- Cited by
- 201
- References
- 6
- FWCI
- 27.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme. https://app.cochat.ai/papers/10.1093/eurheartj/ehac495
- The paper
- Zannad, F., Ferreira, J. P., Butler, J., Filippatos, G., Januzzi, J. L., Sumin, M., Zwick, M., Saadati, M., Pocock, S. J., Sattar, N., Anker, S. D., & Packer, M. (2022). Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme. European Heart Journal. https://doi.org/10.1093/eurheartj/ehac495
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.